Pöördumine

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Ref.: C.L.22.2023 The World Health Organization (WHO) presents its compliments to Member States and Associate Members and has the pleasure of announcing that the 46th Expert Committee on Drug Dependence (ECDD) will meet from 16 to 20 October 2023 in Geneva, Switzerland. Given that WHO Expert Committee meetings are of a closed nature, this letter serves to notify Member ... States of the substances under review at the 46th ECDD, which are in the Annex I file, attached for reference. WHO is mandated by the 1961 and 1971 International Drug Control Conventions to make recommendations to the UN Secretary-General on the need for and level of international control of psychoactive substances based on the advice of its independent scientific advisory body, the ECDD. To assess whether or not a psychoactive substance should be placed under international control, the ECDD convenes annually to review the potential of this substance to cause dependence, abuse and harm to health, as well as any therapeutic applications. In order to perform this review and make evidence-based decisions, the ECDD conducts medical, scientific, and public health evaluations of the selected psychoactive substances using the best available information. Although the meetings are of a closed nature, Member States are invited to contribute to the ECDD review process by joining the 46th ECDD Information Session on 16 October 2023. The Information Session will be held virtually and allow interested parties to learn about present and future activities of the ECDD Secretariat, and to present information concerning substances under review to the 46th Expert Committee for consideration in its deliberations. Registration information will be made available on the ECDD web site in due course: https://www.who.int/news-room/events/detail/2023/10/16/default-calendar/forty-sixth-expert- committee-on-drug-dependence. As in the past and in line with the publication “Guidance on the WHO review of psychoactive substances for international control” (EB126/2010/REC1, Annex 6),1 Member States can also contribute to the ECDD review process by providing up to date and accurate information concerning the substances under review in advance of the meeting. For this purpose, and as per previous practice, a questionnaire will be sent to Member States to gather country information on the legitimate use, harmful use, status of national control and potential impact of international control for each substance under evaluation. 1 https://apps.who.int/gb/ebwha/pdf_files/EB126-REC1/B126_REC1-en.pdf#page=90. ... ENCLS.: (2)  Page 2 C.L.22.2023 ... Annex II to this Circular Letter contains a list of national focal points officially designated by Member States in previous years who provide country information to the ECDD through the Member States questionnaire referred to above. If the focal point information requires changes or amendments, Member States are invited to inform the WHO ECDD Secretariat by email to [email protected] by 11 July 2023 with the subject “46ECDD Focal Point: (Country Name)”. If the individual on the list is still the official focal point for completing the ECDD Member State questionnaire this year and if no additions or amendments to focal point details are made by 11 July 2023, the focal point from the list will be given further instructions and direct access to online questionnaires by the WHO Secretariat. Results of the questionnaires will be prepared as a report as part of the 46th ECDD substance review process. In addition to the questionnaire, Member States are also encouraged to provide any additional relevant information (unpublished or published) on substances to be reviewed by the 46th ECDD by emailing [email protected] with the subject “Ref: C.L.22.2023”. All recommendations made by the 45th ECDD, held in October 2022, were accepted by the 66th UN Commission on Narcotic Drugs and all technical reports and recommendations made by the ECDD are available online through the recently launched ECDD Information Repository (https://ecddrepository.org/en). The World Health Organization takes this opportunity to renew to Member States and Associate Members the assurance of its highest consideration. GENEVA, 27 June 2023 Annex I 46th Expert Committee on Drug Dependence (ECDD) Substances for review 16–20 October 2023 Critical reviews: The substances listed below have been proposed by WHO for critical review and are not currently under international control. Information was brought to WHO’s attention that these substances are clandestinely manufactured, of especially serious risk to public health and society, and of no recognised therapeutic use by any Party. The Expert Committee will consider whether information presented during a critical review may justify the scheduling or a change in the scheduling of the substance in the 1961 or 1971 Conventions. Benzodiazepines 1. Bromazolam 2. Flubromazepam Novel synthetic opioids 3. Butonitazene Cathinones/stimulants 4. 3-CMC 5. Dipentylone Dissociative-type substances 6. 2-fluorodeschloroketamine Pre-reviews: The substances listed below have been proposed for a pre-review. The purpose of a pre-review is to determine whether current information justifies an Expert Committee critical review. A pre-review is a preliminary analysis and findings at this stage should not determine whether the control status of a substance should be changed. Medicines 7. Nitrous oxide 8. Carisoprodol WHO Expert Committee on Drug Dependence (ECDD): List of National Focal Points The contact details below are provided by the national authorities as focal points for the WHO Expert Committee on Drug Dependence (ECDD). Please send notifications about changes to [email protected]. A Afghanistan No information Albania Linda Ternova Specialist Regulation Sector of Pharmaceutical Market and Medical Devices Ministry of Health and Social Protection, Albania Email: [email protected] Algeria Ghrieb Houria Doctor Narcotics, Psychotropics and Chemical precursors General Direction of Pharmacy and Health Equipment Algerian Ministry of Health Email: [email protected] Andorra Carla Lobaco Valls Technical Officer Department of Health Resources and Medicines Email: [email protected], Carme Pallarés Papaseit Chief of Department Department of Health Resources and Medicines Email: [email protected] Angola No information 1 Antigua and Barbuda No information Argentina G. Rebalderia Pharmacist Director of Surveillance of Substances Subject to Special Control Argentinian Ministry of Health Email: [email protected] Armenia Hasmik Martirosyan Armenian Ministry of Health Email: [email protected] Australia (Last updated 29 June 2022) Alyce Hall Director – Research and International Policy Section Alcohol & Other Drugs Branch, Population Health Division Australian Government Department of Health and Aged Care Email: [email protected], [email protected] Austria Raphael Bayer Head of Division Section VI, Department 6 Federal Ministry of Social Affairs, Health, Care and Consumer Protection Email: [email protected] Azerbaijan Telman Suleyman Oglu Mammadhassanov Email: [email protected] B Bahamas No information Bahrain Samar Yousef Salem Senior Pharmacist Ministry of Health Kingdom of Bahrain Email: [email protected] 2 Bangladesh (Last updated 17 June 2022) Kazi Zebunnessa Begum Additional Secretary (World Health Branch) Health Services Division Ministry of Health & Family Welfare Email: [email protected] Barbados Maryan Hinds Director of the Barbados Drug Service Ministry of Health Email: [email protected] Belarus Aleksey Kralko Ministry of Health Email: [email protected] Belgium Lies Gremeaux Head of Unit illicit Drugs, Reitox National Focal Point Epidemiology and Public Health, Sciensano Ministry of Health Email: [email protected] Belize No information Benin (Last updated 30 June 2022) Saturnin Bognon State-certified Pharmacist, Head of Pharmaceutical Establishments Department Email: [email protected] Bhutan Dilk Kumar Subba Department of Public Health Ministry of Health Email: [email protected] Bolivia (Plurinational State of) Maria Julia Carrasco Email: [email protected] 3 Bosnia and Herzegovina Ana Cvijanović Expert Advisor Agency for medical drugs Ministry of Health Email: [email protected] Sabina Šahman Department for Health Ministry of the Civil Affairs of Bosnia and Herzegovina Email: [email protected] Botswana Vivian Sebako Chief Pharmacist, Department of Clinical Services Ministry of Health and Wellness Private BAG 0038 Gaborone, Botswana Email: [email protected] Brazil (Last updated 1 July 2022) Renata de Morais Souza Manager, Management of Controlled Products GPCON/GGMON/DIMON/ANVISA Controlled Substances Office Brazilian Health Regulatory Agency – ANVISA Email: [email protected] Thiago Brasil Silvério, Moema Luisa Silva Macedo Management of Controlled Products GPCON/GGMON/DIMON/ANVISA Controlled Substances Office Brazilian Health Regulatory Agency – ANVISA Email: [email protected] Brunei Darussalam Hajah Zanatul ‘Aini Haji Zainin Acting Director of Pharmaceutical Services Department of Pharmaceutical Services Ministry of Health Email: [email protected] 4 Bulgaria Slaveyka Nikolova Chief Expert at the Health Promotion Department Health Promotion and Prophylaxis of the Diseases and Addictions Directorate Email: [email protected] Alexander Panayotov Head of the National Focus Center Department Mental Health and Addiction Prevention Directorate, National Center for Public Health and Analysis Email: [email protected] Burkina Faso Email: [email protected] Burundi (Last updated 2 July 2022) Israël Nimubona Email: [email protected] C Cabo Verde Fernanda Marques Executive Secretary Commission for the Coordination of Alcohol and Other Drugs Ministerio da Saude e da Seguranca Social Email: [email protected] Cambodia Chhit Sophal Director Department of Mental and Substance Abuse Ministry of Health Email: [email protected] Cameroon Ketchozo Loko Wilfried Email: [email protected] Canada (Last updated 23 June 2022) International Relations Unit Office of Drug Policy and Science, Controlled Substances Directorate Health Canada, Government of Canada Email: [email protected] Central African Republic No information 5 Chad Haoua Haroun Saker Deputy Director of Pharmacy and Medicine Ministry of Public Health Email: [email protected] Chile Javiera Erazo Leiva Advisor Department of Mental Health/DIPRECE Ministry of Health Email: [email protected] China (Last updated 29 June 2022) Zhendong Hua Deputy Director National Narcotics Laboratory Email: [email protected] Yan Zheng Official Office of National Narcotics Control Commission Email: [email protected] Peng Xu Senior Expert National Narcotics Laboratory Email: [email protected] Colombia Oscar Ricardo Santana Observatorio de Drogas de Colombia Dirección de Políticas de Drogas y Actividades Relacionadas Ministerio de Justicia y del Derecho Email: [email protected], [email protected] Ana Maria Penuela, Advisor to the Minister’s Office Coordinator of the Social Coexistence and Citizenship Group of the Directorate of Promotion and Prevention Email: [email protected] Cook Islands (Last updated 18 July 2022) Tereapii Uka, Central Policy and Planning Office Email: [email protected] 6 Costa Rica Marchena Vasquez Email: [email protected] Côte d'Ivoire Ernest Zotoua Email: [email protected] Croatia Romana Katalinić Head of Sector Administration for Primary Health Care, Health Tourism, Medicines and Medical Products, Public Health and Public Health Protection Ministry of Health Email: [email protected] Cuba No information Cyprus John Kkolos, Pharmacist Pharmaceutical Services Ministry of Health Email: [email protected] Czechia Vlastimil Brandejs Inspectorate Department, Narcotic and Psychotropic Substances Ministry of Health Email: [email protected] D Democratic People’s republic of Korea Kim Jong Guk Democratic Republic of the Congo (Last updated 19 July 2022) Ghislaine Mbelu Kanyunya Email: [email protected] Denmark Kari Gragaasen Chief Consultant Head of Focal Point, Prevention National Board of Health Email: [email protected] 7 Djibouti No information Dominica (Last updated 19 September 2022) Laura Esprit Chief Medical Officer Ministry of Health, Wellness and New Health Investment Email: [email protected] Anna Royer-Edmund Chief Pharmacist Ministry of Health, Wellness and New Health Investment Email: [email protected] Dominican Republic Francisca Dalia Castillo Sanchez Head of the Assistive Technology Department General Directorate of Medicines, Food and Health Products (DIGEMAPS) Ministry of Public Health Email: [email protected] E Ecuador (Last updated 19 July 2022) María Ignacia Páez Monge International Drug Commissioner and Head of the Management functions of the Project for the Creation and Implementation of Services of the Community Mental Health Network and State Addiction Recovery Centers Email: [email protected] Ileana Isabel Espinosa Soto Project for the Creation and Implementation of Services of the Community Mental Health Network and State Addiction Recovery Centers Email: [email protected] Egypt Email: [email protected] El Salvador José Mauricio Bermúdez Recinos Focal Point of the Ministry of Health of El Salvador Health Technology Department Ministry of Health Email: [email protected] Equatorial Guinea No information 8 Eritrea Michael Girmay Haile Email: [email protected] Estonia (Last updated 27 June 2022) Katrin Tomson-Johanson Chief Specialist of Department of Inspection State Agency of Medicines Ministry of Health Email: [email protected] Eswatini No information Ethiopia Baharu Zewdie Moya Email: [email protected] F Fiji Apolosi Vosanibola Chief Pharmacist Ministry of Health Email: [email protected] Finland Katja Pihlainen Finnish Medicines Agency Ministry of Health Email: [email protected] France (Last updated 12 July 2022) Charlotte Pion Steering, Expertise and Addictovigilance Network Assessor Steering Division/Surveillance Department National Agency for the Safety of Medicines and Health Products Email: [email protected] Luciano Amato, Acting Head of Department Regulation of narcotics and psychotropic substances National Agency for the Safety of Medicines and Health Products Email: [email protected] 9 G Gabon Okouyi Ndakissa Directorate of Medicines and Pharmacy Ministry of Health Email: [email protected] Gambia No information Georgia Ketevan Gorozia LEPL State Regulation Agency for Medical Activities Ministry of Labour, Health and Social Affairs of Georgia Email: [email protected] Germany (Last updated 23 June 2022) Annette Hinze Division 122 – Narcotics Law, Traffic in Narcotics, International Narcotic Drug Affairs Federal Ministry of Health Email: [email protected] Ghana Martha Gyansa-Lutterodt Director, Pharmaceutical Services Ministry of Health Email: [email protected] Greece Ioanna Siamou Responsible for the Early Warning System, EKTEPN University Mental Health Research Institute Email: [email protected] Grenada No information Guatemala Erica Janeth Cohobon Lepe Department of Regulation and Control of Pharmaceutical and Related Products of the Ministry of Public Health and Social Assistance of Guatemala Email: [email protected] Guinea No information 10 Guinea-Bissau No information Guyana No information H Haiti Marie Judith Robuste Roche Ministry of Health Email: [email protected] Honduras Alex Virgillo Santos Moreno General Director of the Honduran Institute for the Prevention of Alcoholism, Drug Addiction and Drug Dependence (IHADFA) Email: [email protected] Hungary Timea Kahlesz Deputy Head of Department EMMI Pharmaceutical and Medical Technology Department Email: [email protected] I Iceland Bjarni Sigurðsson Ministry of Health Email: [email protected] India Rakesh Chadda Professor and Head Department of Psychiatry, and National Drug Dependence Treatment Centre All India Institute of Medical Sciences Email: [email protected] Indonesia Agusdini Banun Saptaningsih Director of Pharmaceutical Production and Distribution Directorate General of Pharmaceutical Care and Medical Devices Email: [email protected] 11 Iran (Islamic Republic of) Abdenzadeh Email: [email protected] Alebouyeh Email: [email protected] Ahmad Hajebi Professor of Psychiatry Iran University of Medical Sciences Director General, Department for Mental Health and Substance Abuse Ministry of Health and Medical Education Email: [email protected] Iraq (Last updated 29 July 2022) Emad Abdulrazzaq Abdulghani Ministry of Health Email: [email protected] Ireland (Last updated 21 June 2022) Conor Brennan Department of Health Email: [email protected] Alan Bell Department of Health Email: [email protected] Israel Paola Rosca Head of the Addiction Treatment Department Ministry of Health Email: [email protected] Tal Lavy The Competent Authority for Narcotics, Psychotropics and Precursors Pharmaceutical Administration Email: [email protected] Italy Pietro Canuzzi Medical Doctor Ministry of health – Directorate general of Health Prevention Email: [email protected], Rocco Signorile Central Narcotics Office Ministry of Health Email: [email protected] 12 J Jamaica Lishann Salmon Permanent Mission of Jamaica to the United Nations, Geneva Email: [email protected] Winston De La Haye Ministry of Health Email: [email protected] Michelle Walker Ministry of Foreign Affairs and Foreign Trade Email: [email protected] Japan Compliance and Narcotics Division Pharmaceutical Safety and Environmental Health Bureau Email: [email protected] Jordan Malak Al Mahirah Head of Narcotics, Psychotropic Substances and Chemical Precursors Department Jordan Food and Drug Administration Email: [email protected] K Kazakhstan Prilutskaya Marina Republican Scientific and Practical Center of Mental Health Email: [email protected] Kenya Anthony Toroitich Email: [email protected] Simon Njuguna Email: [email protected] Kiribati Biribo Kararaiti Chief Pharmacist Ministry of Health and Medical Services Email: [email protected] 13 Kuwait Ali Abdulmohsen Jaragh Pharmacist Control of Licenses for Narcotic Drugs and Psychotropic Substances Department Email: [email protected] Kyrgyzstan Kanyshai Damirbek Drug Trafficking Control Department Ministry of Foreign Affairs Email: [email protected] L Lao People’s Democratic Republic Khatthanaphone Phandoangsy Head of Health Promotion and Nutrition Unit Department of Hygiene and Health Promotion Ministry of Health Email: [email protected] Latvia Linda Veisberga Ministry of Health Email: [email protected] Lebanon Marie-Therese Matar Head of Narcotics Department Ministry of Public Health Email: [email protected] Lesotho Masello Sello Email: [email protected] Liberia No information Libya No information Lithuania Rima Mačiūnienė Head of Drug Precursors Control and Risk Assessment Division Drug, Tobacco and Alcohol Control Department Email: [email protected] 14 Luxembourg Alain Origer National Drug Coordinator Ministry of Health Email: [email protected] M Madagascar (Last updated 22 June 2022) Maximine Ravaoarimanana Director of Pharmacy Laboratories and Traditional Medicine Email: [email protected] Malawi Michael Udedi Assistant Director of Clinical Services (Mental Health and Substance Abuse) Email: [email protected] Malaysia Rohaida Binti Zakaria Senior Principal Assistant Director Pharmaceutical Services Division Ministry of Health Email: [email protected] Maldives Aishath Mohamad, Deputy Director General, Pharmaceuticals Medicine and Therapeutic Goods Division Maldives Food and Drug Authority Email: [email protected] Mali Mahamadou Ousmane Maiga Email: [email protected] Malta Victor P. Pace Office of the Superintendence of Public Health Department for Health Regulation Email: [email protected] Marshall Islands Julia Alfred Ministry of Health Email: [email protected] 15 Mauritania Hamoud Fadel Yamohomed Director of Pharmacy and Laboratories Ministry of Health Email: [email protected] Mauritius (Last updated 12 July 2022) Vijayesing Dinassing Ministry of Health and Wellness Email: [email protected] Anil Jhugroo Office Management Executive for Senior Chief Executive Ministry of Health and Wellness Email: [email protected] Mexico (Last updated 21 June 2022) Angélica Juárez Ramírez Specialized Reviewer COFEPRIS representative, Federal Committee for Protection from Sanitary Risks Email: [email protected] Micronesia (Federated States of) Benido Victor [email protected] Monaco Isabebelle Kessedijan Head of Division Pharmacy Inspector Health Products Division Email: [email protected] Mongolia No information Montenegro Jasna Sekulic Ministry of Health Email: [email protected] 16 Morocco Hassan Elkarimi Email: [email protected] Jallal Toufiq Professor of Psychiatry, Rabat Faculty of Medicine Director of the National Centre on Drug Abuse Prevention, Treatment and Research Director of the Moroccan Observatory on Drugs and Drugs Addictions Email: [email protected] Mozambique Eugénia Guelfrida Salesio Teodoro Email: [email protected] Myanmar Nanda Myo Aung Wan Program Manager/Consultant Psychiatrist Drug Dependency Treatment and Research Unit Ministry of Health and Sport Email: [email protected] N Namibia Ester Mvula Senior Pharmacist Ministry of Health & Social Services Email: [email protected] Nauru Richard Leona Chief Surgeon Ministry of Health Email: [email protected] Nepal No information Netherlands (Kingdom of the) Liefke Huizinga Nutrition, Health Protection and Prevention Department Ministry of Health, Welfare and Sport Email: [email protected] 17 New Zealand (Last updated 17 August 2022) Joanna Tomlin Advisor Regulatory Practice and Analysis Medsafe Email: [email protected] Tania Jones Regulatory Practice and Analysis Medsafe Email: [email protected] Eddy Sommers Senior Policy Analyst Ministry of Health Email: [email protected] Nicaragua Karla Vanessa Delgado Martinez Director of Pharmacy Ministry of Health Email: [email protected] Niger Haoua Na Allah Alou Email: [email protected] Nigeria Rafiu Akanbi Head Narcotics and Drug Abuse Programme Narcotics and Drug Abuse Programme, Pharmaceutical Services Division Department of Food and Drug Services Federal Ministry of Health Email: [email protected] Niue No information North Macedonia No information Norway Anne S. Onsgård Sagabråten Narcotic Drugs Control Norwegian Medicines Agency Email: [email protected] 18 O Oman Mahmood Al Abri Email: [email protected] Directorate General of Pharmaceutical Affairs and Drug control Ministry of Health Email: [email protected] P Pakistan Rizwan Taj Professor Ministry of Health Email: [email protected] Palau Clarette Matlab Chief Pharmacist Division of Ancillary Services Bureau of Hospital and Clinical Services Ministry of Health Email: [email protected], [email protected] Marla Ito Email: [email protected] Panama (Last updated 30 June 2022) Juana Herrera Head of Mental Health General Directorate of Health Email: [email protected] Papua New Guinea Vicky Wari Program Manager – Non Communicable Diseases Public Health Division National Department of Health Email: [email protected] Paraguay No information 19 Peru Judith Castañeda Alcántara Head of Functional Unit of Controlled Products DIGEMID – General Directorate of Medicines, Supplies and Drugs Email: [email protected] Philippines No information Poland Michał Kidawa, Polish Reitox Focal Point Information Centre for Drugs and Drug Addiction (CINN) National Bureau for Drug Prevention Email: [email protected] Portugal Graça Vilar Director of Planning and Intervention Services Directorate Intervention Service for Addictive Behaviours and Addictions General Directorate for Intervention on Addictive Behaviours and Dependencies SICAD Email: [email protected] Puerto Rico No information Q Qatar Majid Ali Al Abdulla Senior Consultant Psychiatrist Director of addiction and CL at Hamad Medical Corporation Deputy Chairman of Mental Health Services Hamad Medical Corporation Email: [email protected] R Republic of Korea Hyun Jun Kim Narcotics Policy Division of Ministry of Food and Drug Safety Email: [email protected] 20 Republic of Moldova (Last updated 24 June 2022) Oleg Costachi Standing Committee on Drugs Control Agency for Medicines and Medical Devices Email: [email protected] Romania Camelia Bunaciu Senior Advisor Ministry of Health Email: [email protected] Russian Federation (Last updated, 14 December 2022) Alyona Ryzova Deputy Head of the Unit for regulatory and legal regulation of pharmaceutical activities, regulation of narcotic drugs and psychotropic substances Department for regulation of medicines and medical devices Ministry of Health Email: [email protected] Rwanda No information S Saint Kitts and Nevis No information Saint Lucia Paul Caleb Programme Officer Substance Abuse Advisory Council Secretariat Ministry of Health and Wellness Email: [email protected] Charmaine Emmanuel Coordinator of the Substance Abuse Advisory Council Secretariat Substance Abuse Advisory Council Secretariat Ministry of Health and Wellness Email: [email protected] Saint Vincent and the Grenadines No information Samoa Robert Thomsen Assistant Chief Executive Officer HSPQA, Medical and Allied Division Email: [email protected] 21 San Marino Claudio Muccioli Health Authority Director Health Authority Email: [email protected] Sao Tome and Principe No information Saudi Arabia Adnan Alshammary Administration of controlled preparations Executive Management for Regulatory Affairs Controlled Products Department Regulatory Affairs Directorate Drug Sector Email: [email protected] Senegal (Last updated 14 August 2022) Moussa Diallo Pharmacist Inspector Pharmaceutical Regulatory Agency Ministry of Health and Social Action Email: [email protected] Serbia Nataša Savić Monitoring Centre for Drugs and Drug Addiction Sector for Medicines and Medical Devices, Psychoactive Controlled Substances and Precursors Ministry of Health Email: [email protected] Seychelles No information Sierra Leone No information Singapore Ong Lay Tin Personal Assistant to Director (International Cooperation) Senior Executive (International Cooperation) Public Health Group Ministry of Health Email: [email protected] 22 Slovakia Jan Lehotsky, Reitox National Focal Point National Monitoring Centre for Drugs Department of Anti-Drug Strategy Coordination and Drug Monitoring Ministry of Health of the Slovak Republic Email: [email protected] Slovenia Joze Hren Secretary Directorate of Public Health Ministry of Health Email: [email protected] Solomon Islands Paul Orotaloa Head of Mental Health Services National Mental Health Service Ministry of Health and Medical Services Email: [email protected] Stephen Araitewa Director Mental Health National Mental Health Service Ministry of Health and Medical Services Email: [email protected] Somalia No information South Africa MG Molewa Ministry of Health Email: [email protected] South Sudan (Last update 15 August 2022) Moses Malual Deng Director General of Pharmaceuticals and Medical Supplies Ministry of Health Email: [email protected] 23 Spain Manuel Ibarra Head of Department Inspection & Enforcement Spanish Agency of Medicines and Medical Products (AEMPS) Email: [email protected], Lidia Fernandez Matellano Narcotics and Psychotropic Substances Area Pharmaceutical Inspection and Enforcement Department Spanish Agency of Medicines and Medical Products (AEMPS) Email: [email protected] Sri Lanka S.C. Wickramasinghe Deputy Director General (NCD) Ministry of Health Email: [email protected] Sudan No information Suriname No information Sweden David Lorentzon Deputy Director Ministry of Health and Social Affairs Division for Public Health and Health Care Email: [email protected] Switzerland Diane Steber Federal Department of Home Affairs FDHA Federal Office of Public Health FOPH Division of International Affairs Global Health Section Email: [email protected] Syrian Arab Republic Ahmed Al-Salama Mental Health Directorate Ministry of Heal Email: [email protected] 24 T Tajikistan (Last updated 12 August 2022) Salim Abdulazizov Email: [email protected] Thailand (Last update 30 June 2022) Chantharakul Pharmacist Narcotics Control Division (Standards and Regulations Sub-Division) Food and Drug Administration Ministry of Public Health Email: [email protected] Chavanich Pharmacist Narcotics Control Division (Standards and Regulations Sub-Division) Food and Drug Administration Ministry of Public Health Email: [email protected] Tontisirin Director of Narcotics Division Narcotics Control Division Food and Drug Administration Ministry of Public Health Email: [email protected] Timor-Leste Suzana Soares Henriques Regulatory Affairs Pharmacist Pharmacovigilance and Medicine Control Department National Directorate for Pharmaceutical and Medicines Ministry of Health Email: [email protected] Togo Mouhoudine Yerima Centre National de Pharmacovigilance (CNPV) Email: [email protected] Tokelau No information 25 Tonga Melenaite Mahe Principal Pharmacist Central Pharmacy and Medical Store Old Vaiola Ministry of Health Email: [email protected] Trinidad and Tobago Rohit Doon Adviser Health Promotion Communications and Public Health Ministry of Health Email: [email protected] Tunisia No information Türkiye Demet Aydınkarahaliloğlu Head Turkish Medicines and Medical Devices Agency Pharmacovigilance and Controlled Substances Department Ministry of Health Email: [email protected] Turkmenistan No information Tuvalu No information U Uganda Hafsa Lukwata Head of Mental Health and Control of Substance Abuse Mental Health and Control of Substance Abuse Division Ministry of Health Email: [email protected] 26 Ukraine (Last update 12 August 2022) Irina Pinchuk Director, Institute of Psychiatry of Taras Shevchenko National University of Kyiv Vice-President of the Ukrainian Psychiatric Association Director, International Technology Transfer Center – Ukraine Head of ISSUP Ukraine National Chapter Email: [email protected] Yulia Yachnyk Clinical Psychologist Institute of Psychiatry, Taras Shevchenko National University of Kyiv Email: [email protected] Sergii Shum Deputy Director Institute of Psychiatry, Forensic Psychiatric Examination and Drug Monitoring Email: [email protected] United Arab Emirates (Last updated 22 June 2022) Alia Bin Hussain Head of Regulating Controlled substances Product & Precursor Chemicals Drug Department Ministry of Health and Prevention Email: [email protected] United Kingdom of Great Britain and Northern Ireland (Last updated 19 August 2022) Alberto Oteo Project Manager Drugs Research and Surveillance Addiction and Inclusion Directorate Office for Health Improvement & Disparities Department of Health and Social Care Email: [email protected] United Republic of Tanzania (Last updated 30 September 2022) Goodluck Tumaini Mtei Ministry of Health Email: [email protected] United States of America (Last updated 5 July 2022) Edward Greg Hawkins Controlled Substance Staff Center for Drug Evaluation and research U.S. Food and Drug Administration Email: [email protected] Uruguay Horacio Porciuncula Mental Health Program Area Ministry of Public Health Email: [email protected] 27 Uzbekistan No information V Vanuatu Jerry Iaruel Tafea Provincial Health Administrator Lenakel Health Office Ministry of Health Email: [email protected] Venezuela (Bolivarian Republic of) No information Viet Nam Mhin Tam Nguyen Regulatory Affair Consultant Ministry of Health Email: [email protected] Y Yemen No information Z Zambia Nita Besa Head Clinical Care Chainama Hospital Email: [email protected] Zimbabwe Eneti Siyame Mental Health Manager Ministry of Health and Child Care Email: [email protected] 28 Saatja: <[email protected]> Saadetud: 27.06.2023 17:44 Koopia: <[email protected]> Teema: WHO: C.L.22.2023 (46th ECDD) Manused: C.L.22.2023 (46th ECDD) Arabic.pdf; C.L.22.2023 (46th ECDD) Chinese.pdf; C.L.22.2023 (46th ECDD) English.pdf; C.L.22.2023 (46th ECDD) French.pdf; C.L.22.2023 (46th ECDD) Russian.pdf; C.L.22.2023 (46th ECDD) Spanish.pdf Dear Member States of the World Health Organization, Please find attached, in the six official languages, C.L.22.2023 regarding the 46th Expert Committee on Drug Dependence (ECDD). Should you have questions regarding C.L.22.2023 please send an email to [email protected]. Best regards, Department of Governing Bodies World Health Organization ***DO NOT RESPOND TO THIS E-MAIL. YOU WILL NOT RECEIVE A REPLY***